Reviews/Chronic Spontaneous Urticaria Treatment/IgE predicts omalizumab response
Omalizumab · CSU-OMA-02 · v2
In chronic spontaneous urticaria, omalizumab helps many patients but not all, and clinicians want a simple blood test to tell in advance who will benefit. Several studies measured patients' total IgE before starting the drug and found that non-responders tended to have lower starting IgE while responders tended to have higher levels [1][13][18]. This pattern appeared in three separate patient groups, which is why the panel accepted the general direction of the claim. But these were observational studies with fairly small numbers, and the link is a group-level trend rather than a proven test that reliably forecasts an individual's outcome. One study found that the change in IgE after four weeks of treatment forecast non-response better than the starting level alone [1], and another found starting IgE was a weaker signal than other markers [18]. Low IgE may also simply mark a particular autoimmune subtype of the disease rather than acting as an independent predictor.
Three independent cohorts consistently show lower baseline total IgE in omalizumab nonresponders and higher levels in responders. In [1] (n=113), nonresponders had baseline IgE of 17.9 IU/mL versus 82.0 in partial responders (P=.008) and 73.7 in complete responders (P=.032). [13] (n=25) found baseline IgE of 16±24 kUA L−1 in nonresponders versus 115±432 in partial and 148±114 in complete responders, differing between responders and nonresponders at P=0.004. In [18] (n=363), a baseline IgE level ≤40 IU/mL was more common among subjects with poor symptom control at 12 weeks (50% vs 33%). The effects agree in direction but rest on modest, observational samples. The contested point: The division is whether baseline IgE 'predicts' response or merely differs between groups. [1] reports the on-treatment w4IgE/bIgE ratio predicted non-response significantly better than baseline IgE alone (P=.016), and [18] shows baseline IgE is a weaker signal than CU Index (OR 2.54, P=.0002) and is clearly predictive only when combined with low blood histamine content.
All 20 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Chronic Spontaneous Urticaria Treatment, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
'Predicts' overstates the evidence: the included studies demonstrate group-level associations (responders differ in baseline IgE), not validated predictive performance; [18] shows baseline IgE is a weaker signal than CU Index (OR 2.54, P=.0002) and is clearly predictive only combined with low blood histamine content.
[1], the study most cited for the claim, explicitly reports that the w4IgE/bIgE ratio predicted nonresponse 'significantly better than by bIgE levels (P = .016)', demoting baseline IgE alone as the predictor.
Where it remains uncertain. [1] found the on-treatment w4IgE/bIgE ratio predicts non-response better than baseline IgE alone (P=.016), and [18] ranks baseline IgE below CU Index (OR 2.54, P=.0002).
Aleatory
[13] rests on only five nonresponders with wide dispersion (partial responders 115±432 kUA L−1), so the group means are statistically unstable.
Epistemic
The supporting cohorts [1][13][18] are observational with modest N, and the corpus contains no prospective validation of a predictive baseline IgE threshold.
Inferential
The corpus shows responders differ in baseline IgE, but 'predicts' requires validated predictive accuracy; [1] shows the on-treatment ratio outperforms baseline alone (P=.016).
The load-bearing papers from a corpus of 20, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Prospective cohort (n=113) showing baseline IgE differs by response category in the claimed direction.
“Nonresponders to omalizumab had significantly lower bIgE levels (17.9, 17.0-55.0 IU/mL) than partial responders (82.0, 46.2-126.5 IU/mL, P = .008) and complete responders (73.7, 19.45-153.8 IU/mL, P = .032).”
Panel auditInternal validity: medium · scope of inference: CSU patients treated with omalizumab 300 mg/4 weeks for 12 weeks; baseline IgE as a response predictor.Key limitations: observational · no adjustment reported · 12-week endpoint only
Independent cohort (n=25) replicating the lower-baseline-IgE-in-nonresponders direction.
“Baseline IgE levels were significantly lower in nonresponders (16 ± 24 kUA L−1) than in partial responders (115 ± 432 kUA L−1; P = 0.017) and complete responders (148 ± 114 kUA L−1; P = 0.004).”
Panel auditInternal validity: low · scope of inference: Baseline IgE and D-dimer as predictors of omalizumab response in severe antihistamine-refractory CSU.Key limitations: very small sample · few nonresponders · no adjustment
Largest primary dataset (n=363, pooled phase III) confirming low baseline IgE associates with poorer response.
“Subjects with UAS7 higher than 6 at 12 weeks significantly more often expressed a baseline negative biopredictor: IgE level less than or equal to 40 IU/mL (n = 109 [50%]) versus IgE level more than 40 IU/mL (n = 239 [33%])”
Panel auditInternal validity: medium · scope of inference: Negative biopredictors (low IgE, positive CUI, low BHC) of omalizumab response at 12 weeks in antihistamine-refractory CSU.Key limitations: retrospective post hoc · IgE dichotomized at 40 IU/mL · explicit p/OR given for CUI not IgE alone
The only readable result sentence states no differences between the three responder groups, which contradicts the title and sits in a truncated, garbled abstract, so direction is not determinable.
Panel auditInternal validity: not assessable from abstract · scope of inference: Total IgE and omalizumab response across responder categories at four GA2LEN centres.Key limitations: abstract truncated/garbled · title and body conflict · no readable effect estimate
4 of 20 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Consistent directional association across independent cohorts, but observational design, modest robustness and 'predicts' overreaching validated performance cap it at Likely.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Validated predictive accuracy for baseline IgE. The corpus shows group differences, not the sensitivity or specificity of a baseline IgE cut-off for individual response. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Prospective diagnostic-accuracy cohort with a pre-specified baseline IgE threshold and reported ROC, sensitivity and specificity against 12-week response.
Open question: Does a pre-specified baseline total IgE threshold predict individual omalizumab response with clinically useful accuracy? Why it is still open: The supporting studies [1][13][18] report group-level differences but no validated predictive metrics.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19